Dimerix Limited (ASX: DXB) has acquired DMX-652, a drug candidate targeting acute kidney injury (AKI), from UK-based Mission Therapeutics, according ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE